Company intelligence / Profile preview
Cambium Bio
Paddington, New South Wales, Australiacambium.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Advancing Elate Ocular® towards pivotal Phase 3 trials in early 2025; patient dosing planned to begin April 2025 with trial readouts mid 2026. FDA has approved potency assay strategy for Elate Ocular®.
- Therapeutic areas
- DermatologyOphthalmologyRheumatology
- Modalities
- BiologicStem cell therapyPlatelet lysate-based therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Zheng Yang Biomedical Technology (ZYBT) – manufacturing partnership and sublicensing agreement for Aurarix® FD-HPL technology.AventaCell – affiliate of ZYBT involved in manufacturing/commercialization.
Beyond the preview
Go deeper on Cambium Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cambium Bio.